GHP Healthcare & Pharmaceutical Awards 2018

6 GHP / 2018 Healthcare & Pharmaceutical Awards Since its inception in 2007 Accell has flourished, and today the firm offers a full range of services in clinical study management for Phase I-III studies. With four offices and local staff, the firm covers more than 15 countries within the Eastern European region. Alongside its work in clinical studies, Accell also partners with other CROs that want to expand their geographic reach into Eastern Europe in order to speed up patient recruitment. Svetlana shares an insight into the firm’s aims and how it works to achieve these. “Here at Accell, our mission is simple: to give patients hope. , Best Clinical Trial Management Firm - Eastern Europe Accell Clinical Research is a niche clinical research organization (CRO) that focuses on delivering high quality clinical trial services in Eastern Europe, CIS, and Russia. We spoke to Svetlana Kazanskaya, Accell’s Director of Business Development, to learn more about the firm and the fascinating work it undertakes. We truly believe that bringing more oncology clinical trials into our area could be a life-saving solution to people in desperate need for treatment. To do so, we have a dedicated team of staff who are truly exceptional and work hard to drive our firm towards this ambition. Everyone from Director of Clinical Operations to project managers, CRAs, and assistants make their priority to deliver on promises. “People is are our main focus, both on Sponsor’s side and internally. This is the reason why Accell gets an 80% return business and no more than 5% employee turnover rate. We are proud about having people who work with Accell since its foundation more than a decade ago. Dictated by our human-approach, we also take work personally meaning that our goal is to actually solve our client’s problem taking away all his headaches. Our principle is not to be a Sponsor’s vendor but becoming their trusted partner and making business in a close partnership-like collaboration.” “Most Sponsors’ headaches these days is slow patient recruitment. The numbers are dreadful: 80% of all clinical trials fall behind schedule and a third of clinical sites never enrol a single patient. So, these delays create a huge impact on the untimely product market launch and companies’ financial losses due to not keeping up with set deadlines. At Accell we have been historically high- recruiters in various indications always making sure our studies are performed on time. With a particular success in oncology patient recruitment, we managed to rescue a number of studies that were severely falling behind the schedule when Sponsors addressed Accell for help.” “Many erroneously believe that it is more complicated to run a clinical trial in this territory than in the USA or Western Europe due to logistics, linguistic, or regulatory aspects. In fact, it is not so if a company manages to get a guidance from an experienced partner. The region has tremendously evolved in past decades making one of the best places to go to get high quality of data that receives regulatory agencies recognition worldwide. Both FDA and EMA willingly